The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Challenges in the approval of therapies for GI cancers
Lola A. Fashoyin-Aje, MD, MPH, U.S. Food and Drug Administration, outlines challenges associated with the approval of therapies for gastrointestinal (GI) malignancies and why approaches such as immunotherapy, which has been successful in other disease areas, has not been applicable to the GI space. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
